Metastatic lung cancer | Treatment of stage IV lung cancer | Immunotherapy | Targeted therapy

1 Views

07/07/23

"Lung Cancer: Controversies to Consensus" webinar was held virtually on 13.03.2022. Mutation driven lung cancer should be treated with targeted therapy. Although there are phase III trial of targeted therapies like EGFR, ALK, ROS1 targeting agents, there are harding any phase III data on rare mutations like BRAF, MET, RET etc. Immunotherapy alone or in combination with chemotherapy has shown promising results stage IV NSCLC. In In this session of panel discussion, we tried to explore whether Immunotherapy +/- chemotherapy could be the standard of care in stage IV NSCLC with rare mutations positive disease.

best oncologist in kolkata
www.dranimeshsaha.com